Comparative Pharmacology
Head-to-head clinical analysis: DOXERCALCIFEROL versus DRISDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXERCALCIFEROL versus DRISDOL.
DOXERCALCIFEROL vs DRISDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxercalciferol is a synthetic vitamin D2 analog that undergoes hepatic conversion to its active metabolite, 1α,25-dihydroxyvitamin D2, which binds to the vitamin D receptor (VDR) in the parathyroid glands, reducing parathyroid hormone (PTH) synthesis and secretion. It also increases intestinal calcium and phosphate absorption and promotes bone mineralization.
Drisdol (ergocalciferol) is a vitamin D2 analog that increases intestinal absorption of calcium and phosphate, promotes renal tubular reabsorption of calcium, and stimulates bone mineralization by binding to vitamin D receptors, which regulate gene expression.
0.5 mcg orally three times per week at each hemodialysis session; alternatively, 1 mcg orally three times per week. Intravenous: 0.5 mcg bolus three times per week at end of hemodialysis; titrate to target intact parathyroid hormone (iPTH) level.
50,000 IU orally once weekly for 8 weeks, then 50,000 IU orally once monthly for maintenance.
None Documented
None Documented
Clinical Note
moderateDoxercalciferol + Hydrochlorothiazide
"Doxercalciferol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateDoxercalciferol + Bendroflumethiazide
"Doxercalciferol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateDoxercalciferol + Methyclothiazide
"Doxercalciferol may increase the hypercalcemic activities of Methyclothiazide."
Clinical Note
moderateDoxercalciferol + Hydroflumethiazide
Terminal elimination half-life is approximately 96 hours (range 48–168 hours) in patients with chronic kidney disease, reflecting slow release from adipose tissue and prolonged vitamin D receptor activation.
Terminal elimination half-life is approximately 19–48 hours after a single oral dose, with clinical context: repetitive dosing increases half-life due to accumulation in adipose tissue, leading to a functional half-life of weeks to months for vitamin D stores.
Primarily fecal (biliary) elimination; renal excretion accounts for <2% of unchanged drug in urine.
Primarily excreted via bile into feces (~90%), with renal excretion accounting for the remainder (~10%). Biliary excretion of metabolites is the major route, with enterohepatic recycling contributing to prolonged elimination.
Category A/B
Category C
Vitamin D Analog
Vitamin D Analog
"Doxercalciferol may increase the hypercalcemic activities of Hydroflumethiazide."